Company · CIK 1760854
Nanobiotix S.A.
| CIK | 1760854 (SEC EDGAR) |
|---|---|
| Industry (SIC) | 2834 — Pharmaceutical Preparations |
| Incorporated in | I0 |
| Business address | France |
| Listed | NBTX (Nasdaq), NNBXF (OTC) |
| First annual or quarterly report | 2021-04-07 |
Offerings
3 registrations| Registration | Label and status | First filed | Last event | Filings |
|---|---|---|---|---|
| 333-285604 | 2025-03-06 | 2026-05-22 | 4 | |
| 333-262545 | 2022-02-04 | 2023-11-06 | 4 | |
| 333-250707 | 2020-11-20 | 2020-12-11 | 5 |
Filings
15| Filed | Filing | Registration | Accession |
|---|---|---|---|
| 2026-05-22 | 424B5Shelf takedown | 333-285604 | 0001140361-26-022604 |
| 2026-05-20 | 424B5Shelf takedown | 333-285604 | 0001140361-26-022247 |
| 2025-03-14 | EFFECTDeclared effective | 333-285604 | 9999999995-25-000694 |
| 2025-03-06 | F-3Shelf registered | 333-285604 | 0001140361-25-007433 |
| 2023-11-06 | 424B5Shelf takedown | 333-262545 | 0001140361-23-051573 |
| 2023-11-02 | 424B5Shelf takedown | 333-262545 | 0001140361-23-050907 |
| 2022-02-16 | EFFECTDeclared effective | 333-262545 | 9999999995-22-000476 |
| 2022-02-04 | F-3Shelf registered | 333-262545 | 0001140361-22-003928 |
| 2020-12-11 | 424B4Final prospectus | 333-250707 | 0001140361-20-028188 |
| 2020-12-10 | EFFECTDeclared effective | 333-250880 | 9999999995-20-003484 |
| 2020-12-10 | EFFECTDeclared effective | 333-250707 | 9999999995-20-003482 |
| 2020-12-09 | F-1/AAmendment | 333-250707 | 0001140361-20-027910 |
| 2020-12-07 | F-1/AAmendment | 333-250707 | 0001140361-20-027413 |
| 2020-11-20 | F-1Registration filed | 333-250707 | 0001140361-20-026217 |
| 2018-12-21 | DRSDraft made public | 377-02433 | 0001140361-18-045590 |